Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Quote | Cellectis S.A. (NASDAQ:CLLS)
Last: | $2.30 |
---|---|
Change Percent: | -8.29% |
Open: | $2.22 |
Close: | $2.30 |
High: | $2.43 |
Low: | $2.157 |
Volume: | 400,310 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Cellectis S.A. (NASDAQ:CLLS)
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
Message Board Posts | Cellectis S.A. (NASDAQ:CLLS)
Subject | By | Source | When |
---|---|---|---|
https://ih.advfn.com/stock-market/NASDAQ/cellectis-$CLLS/stock-news/83912184/cell | Frankestin | investorshub | 01/10/2023 5:27:59 PM |
Cellectis Announces Positive Preliminary Clinical Data for UCART22 | Frankestin | investorshub | 12/14/2022 8:39:18 AM |
will there be something interesting? | Frankestin | investorshub | 11/01/2022 10:53:45 AM |
also interesting here! | Frankestin | investorshub | 06/01/2022 5:10:36 PM |
News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing | whytestocks | investorshub | 10/01/2019 8:40:21 PM |
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...